OncoMatch/Clinical Trials/NCT06349889
Adebrelimab and Chemoradiotherapy in High-risk LANPC
Is NCT06349889 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab for nasopharyngeal carcinoma.
Treatment: Adebrelimab — This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVA+T3N2M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
neutrocyte count ≥1.5×10e9/L, hemoglobin ≥90g/L, platelet count ≥100×10e9/L
Kidney function
creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula)
Liver function
ALT/AST ≤2.5×ULN, bilirubin ≤1.5×ULN
Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L. ALT/AST ≤2.5×ULN, bilirubin ≤1.5×ULN. Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify